×
Zai Lab Total Long Term Liabilities 2016-2025 | ZLAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zai Lab total long term liabilities from 2016 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
Zai Lab Total Long Term Liabilities 2016-2025 | ZLAB
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Zai Lab total long term liabilities from 2016 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$248.3B
Amgen (AMGN)
$155.9B
Gilead Sciences (GILD)
$142.4B
Vertex Pharmaceuticals (VRTX)
$99.3B
Bristol Myers Squibb (BMY)
$96.1B
GSK (GSK)
$81.1B
CSL (CSLLY)
$67.7B
Regeneron Pharmaceuticals (REGN)
$62.3B
Alnylam Pharmaceuticals (ALNY)
$59.1B
Argenex SE (ARGX)
$43.3B
Insmed (INSM)
$27.9B
BioNTech SE (BNTX)
$25.2B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$20B
Incyte (INCY)
$16.4B
Genmab (GNMSF)
$16B
Genmab (GMAB)
$15.7B
Illumina (ILMN)
$15.2B
Ascendis Pharma (ASND)
$12B
BioMarin Pharmaceutical (BMRN)
$11B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.9B
Exelixis (EXEL)
$10.3B
Moderna (MRNA)
$9.6B
Verona Pharma American Depositary Share (VRNA)
$9.1B
Bio-Techne Corp (TECH)
$8.9B
Exact Sciences (EXAS)
$8.7B
Halozyme Therapeutics (HALO)
$8.5B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8.1B